UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

                        Commission File Number: 000-28153

                            CUSIP Number: 830884 10 2

(Check One): [X] Form 10-K  [_] Form 20-F [_] Form 11-K [ ] Form 10-Q
             [_] Form N-SAR [_] Form N-CSR

             For Period Ended: December 31, 2007

             [_] Transition Report on Form 10-K
             [_] Transition Report on Form 20-F
             [_] Transition Report on Form 11-K
             [_] Transition Report on Form 10-Q
             [_] Transition Report on Form N-SAR

             For the Transition Period Ended: ________________________

     Read attached instruction sheet before preparing form. Please print or
 type. Nothing in this form shall be construed to imply that the Commission has
                   verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:
- --------------------------------------------------------------------------------

PART I -- REGISTRANT INFORMATION

SKYSTAR BIO-PHARMACEUTICAL COMPANY
- --------------------------------------------------------------------------------
Full name of registrant:

N/A
- --------------------------------------------------------------------------------
Former name if applicable:

Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South
- --------------------------------------------------------------------------------
Address of principal executive office (Street and number):

Gaoxin District, Xian Province, P.R. China
- --------------------------------------------------------------------------------
City, state and zip code




PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate.)

     |      (a)   The reasons described in reasonable detail in Part III of this
     |            form could not be eliminated without unreasonable effort or
     |            expense;
     |
     |      (b)   The subject annual report, semi-annual report, transition
     |            report on Form 10-KSB, Form 20-F, 11-K or Form N-SAR, or
     |            portion thereof, will be filed on or before the fifteenth
[X]  |            calendar day following the prescribed due date; or the subject
     |            quarterly report or transition report on Form 10-Q, or portion
     |            thereof will be filed on or before the fifth calendar day
     |            following the prescribed due date; and
     |
     |      (c)   The accountant's statement or other exhibit required by Rule
     |            12b-25(c) has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report portion thereof, could not be filed within the
prescribed time period. (Attach extra sheets if needed.)

The Company has experienced a delay in completing the information necessary for
inclusion in its December 31, 2007 Form 10-K Annual Report. The Company expects
to file its Form 10-K Annual Report within the allotted extension period.

PART IV -- OTHER INFORMATION

(1)   Name and telephone number of person to contact in regard to this
      notification

      Francis Chen, Esq.                  (310)      208-1182
      ------------------                ----------- ------------------
            (Name)                      (Area Code) (Telephone Number)

(2)   Have all other periodic reports required under Section 13 or 15(d) of the
      Securities Exchange Act of 1934 or Section 30 of the Investment Company
      Act of 1940 during the preceding 12 months or for such shorter period that
      the registrant was required to file such report(s) been filed? If the
      answer is no, identify report(s). [X] Yes [ ] No

(3)   Is it anticipated that any significant change in results of operations
      from the corresponding period for the last fiscal year will be reflected
      by the earnings statements to be included in the subject report or portion
      thereof? [ ] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.




                       SKYSTAR BIO-PHARMACEUTICAL COMPANY
                  --------------------------------------------
                  (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.


Date: April 1, 2008                         By:   Weibing Lu
                                                  -----------------------
                                                  Weibing Lu
                                                  Chief Executive Officer